These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15308347)

  • 21. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
    Wilson TR
    J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of postvaccinal response in children past pertussis].
    Grzybowska K; Przybyszewski M; Banasik M; Płaneta-Małecka I; Zeman K
    Wiad Lek; 2006; 59(11-12):819-22. PubMed ID: 17427498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of the Biken acellular pertussis vaccine in adults with or without previous vaccination against pertussis in childhood.
    Knuf M; Schmitt HJ; Mohnike K; Zepp F; Habermehl P; Kampmann C; Herden P
    Med Klin (Munich); 2004 Sep; 99(9):495-9. PubMed ID: 15372178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age.
    Nilsson L; Faldella G; Jacquet JM; Storsaeter J; Silfverdal SA; Ekholm L
    Scand J Infect Dis; 2005; 37(3):221-9. PubMed ID: 15849057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Priming with whole-cell versus acellular pertussis vaccine.
    Liko J; Robison SG; Cieslak PR
    N Engl J Med; 2013 Feb; 368(6):581-2. PubMed ID: 23388023
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands.
    de Greeff SC; Mooi FR; Schellekens JF; de Melker HE
    Pediatr Infect Dis J; 2008 Mar; 27(3):218-23. PubMed ID: 18277916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.
    Weston WM; Klein NP
    Expert Rev Vaccines; 2008 Nov; 7(9):1309-20. PubMed ID: 18980534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.